We are monitoring the impact of COVID-19 on Asia Pacific Next Generation Antibody Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 5231
Share on
Share on

Asia Pacific Next Generation Antibody Therapeutics Market Research Report - Segmented By Therapeutics, Technology & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, Growth, Forecast | 2021 to 2026

Pulished: February, 2020
ID: 5231
Pages: 145

The Asia Pacific Next-Generation Antibody Therapeutics Market Size (2021 to 2026):

According to the report, the size of the Asia Pacific Next-Generation Antibody Therapeutics Market is estimated to grow USD 1.77 billion by 2026 from USD 0.88 billion in 2021, growing at a CAGR of 14.9% between 2021 to 2026. It captures 20% of the global market.

Biotechnology and pharmaceutical companies are clinically developing the next-generation antibody therapies for different disease indications accredited to the rise in market growth. Increasing demand for biologics drugs used for treating patients with chronic disorders is leveraging market growth. Rising census count and economies, particularly in developed countries, are projected to lead the market growth. Escalating government support for research and development activities and growing demand for superior healthcare facilities are surging the market demand. A growing number of cancer cases, as the next generation antibody therapy works as an effective therapy accredited to the market growth. Factors like rising government initiatives for supporting research and development activities and developing healthcare infrastructure are fueling the market. New product launches with regular government approvals are incrementing the next-generation antibody therapeutics market demand.

However, the huge capital required for research and development activities in developing antibody therapies negatively affects market growth. The governments of different nations have imposed strict rules and guidelines regarding the usage of antibodies. This factor is curbing the increase in the market. Time taking procedural approvals and limited FDA approvals for drugs and other products restrict the growth in the market.

This research report on the Asia Pacific Next-Generation Antibody Therapeutics Market has been segmented and sub-segmented into the following categories:

By Therapeutics: 

  • Oncology
  • Autoimmune/Inflammatory Diseases

By Technology: 

  • Antibody-Drug Conjugates (ADCs)
  • Bispecific Antibodies (BsAbs)
  • Fc Engineered Antibodies
  • Antibody Fragments and Antibody-like Proteins
  • Biosimilar Antibody Products

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Based on the region, the Asia Pacific is likely to be the fastest-growing market with the highest CAGR in the forecast period. The economic boom in the emerging economies of India and China are the reasons for this.

The Asia-pacific market is accredited due to factors like increasing antibody-drug conjugate usage and rapid growth in biosimilar antibodies and engineered antibodies creating new opportunities for the market demand. Increasing research and development activities united with crucial players to manufacture adequate and enhanced drugs escalates the market demand. China is leading the market with the largest share. The market in China is driven by the government, spending considerable investments in improving healthcare during the COVID-19 pandemic. The escalating number of cost-efficient research services is majorly contributing to the market growth. Japan and China are next to China in leading the next-generation antibody therapeutics market. Rising advancements among the monoclonal antibody technology are likely to foster market growth. A growing number of government initiatives regarding the research and development of drug development and increasing disposable income positively influence the market demand. The rest of APAC is expected to have noticeable growth in the market.

Some of the notable companies dominating the Asia Pacific Next-Generation Antibody Therapeutics Market include Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen, Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc.

1. Introduction          

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods   

                1.4 General Study Assumptions                

2. Research Methodology                    

                2.1 Introduction        

                2.2 Research Phases                      

         2.2.1 Secondary Research           

         2.2.2 Primary Research 

         2.2.3 Econometric Modelling      

         2.2.4 Expert Validation  

                2.3 Analysis Design  

                2.4 Study Timeline   

3. Overview                

                3.1 Executive Summary                

                3.2 Key Inferences  

                3.3 Epidemiology       

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)             

                4.1 Market Drivers   

                4.2 Market Restraints                    

                4.3 Key Challenges  

                4.4 Current Opportunities in the Market       

5. Market Segmentation

                5.1 Technology                 

         5.1.1 Introduction           

         5.1.2 Antibody-Drug Conjugates (ADCs)               

         5.1.3 Bispecific Antibodies (BsAbs)          

         5.1.4 Fc Engineered Antibodies 

         5.1.5 Antibody Fragments and Antibody-like Proteins    

         5.1.6 Biosimilar Antibody Products          

         5.1.7 Y-o-Y Growth Analysis, By Technology        

         5.1.8 Market Attractiveness Analysis, By Technology      

         5.1.9 Market Share Analysis, By Technology        

                5.2 Therapeutic Application 

         5.2.1 Introduction           

         5.2.2 Oncology 

         5.2.3 Autoimmune/Inflammatory Diseases         

         5.2.4 Y-o-Y Growth Analysis, By Therapeutic Application               

         5.2.5 Market Attractiveness Analysis, By Therapeutic Application             

         5.2.6 Market Share Analysis, By Therapeutic Application               

6. Geographical Analysis

                6.1 Introduction        

         6.1.1 Regional Trends    

         6.1.2 Impact Analysis     

         6.1.3 Y-o-Y Growth Analysis        

  6.1.3.1 By Geographical Area

  6.1.3.2 By Technology

  6.1.3.3 By Therapeutic Application

         6.1.4  Market Attractiveness Analysis     

  6.1.4.1 By Geographical Area

  6.1.4.2 By Technology

                    6.1.4.3 By Therapeutic Application

         6.1.5  Market Share Analysis      

  6.1.5.1 By Geographical Area

  6.1.5.2 By Technology

  6.1.5.3 By Therapeutic Application

                6.2 China      

                6.3 India       

                6.4 Japan     

                6.5 South Korea        

                6.6 Australia     

                6.7 Rest of APAC                 

7. Strategic Analysis                

                7.1 PESTLE analysis  

         7.1.1 Political     

         7.1.2 Economic 

         7.1.3 Social         

         7.1.4 Technological         

         7.1.5 Legal          

         7.1.6 Environmental       

                7.2 Porter’s Five analysis       

         7.2.1 Bargaining Power of Suppliers        

         7.2.2 Bargaining Power of Consumers    

         7.2.3 Threat of New Entrants     

         7.2.4 Threat of Substitute Products and Services              

         7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                 

                8.1 Roche    

         8.1.1 Overview 

         8.1.2 Product Analysis   

         8.1.3 Financial analysis  

         8.1.4 Recent Developments       

         8.1.5 SWOT analysis       

         8.1.6 Analyst View          

                8.2 Seattle Genetics

                8.3 Takeda  

                8.4 Dyax Corp.                  

                8.5 Immunogen        

                8.6 Amgen, Inc.         

                8.7 Biogen   

                8.8 Kyowa Hakko Kirin Co., Ltd.                 

                8.9 AstraZeneca        

                8.10 Pfizer, Inc.                

9. Competitive Landscape                    

                9.1 Market share analysis     

                9.2 Merger and Acquisition Analysis

                9.3 Agreements, Collaborations, and Joint Ventures  

                9.4 New Product Launches  

10. Market Outlook and Investment Opportunities                  

Appendix                    

                a) List of Tables                

                b) List of Figures       

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • The segment-level analysis in terms of product type By Technology  market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia Pacific Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  2. Asia Pacific Antibody-Drug Conjugates (ADCs) Market By Region, From 2021 to 2026 ( USD Billion )
  3. Asia Pacific Bispecific Antibodies (BsAbs) Market By Region, From 2021 to 2026 ( USD Billion )
  4. Asia Pacific Fc Engineered Antibodies Market By Region, From 2021 to 2026 ( USD Billion )
  5. Asia Pacific Antibody Fragments and Antibody-like Proteins Market By Region, From 2021 to 2026 ( USD Billion )
  6. Asia Pacific Biosimilar Antibody Products Market By Region, From 2021 to 2026 ( USD Billion )
  7. Asia Pacific Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  8. Asia Pacific Oncology Market By Region, From 2021 to 2026 ( USD Billion )
  9. Asia Pacific Autoimmune/Inflammatory Diseases Market By Region, From 2021 to 2026 ( USD Billion )
  10. Japan Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  11. Japan Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  12. China Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  13. China Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  14. India Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  15. India Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  16. Australia Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  17. Australia Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  18. South Korea Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  19. South Korea Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample